In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors.
Johnson
Kirk W
KW
Neuroscience Research Division, Eli Lilly and Company, Indianapolis, Indianapolis 46285, USA. JOHNSON_KIRK_W@Lilly.com
Clemens-Smith
Amy
A
Nomikos
George
G
Davis
Richard
R
Phebus
Lee
L
Shannon
Harlan
H
Love
Patrick
P
Perry
Ken
K
Katner
Jason
J
Bymaster
Frank
F
Yu
Hong
H
Hoffman
Beth J
BJ
D026921:Amino Acid Transport Systems, Neutral / Q000037:antagonists & inhibitors*; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects*; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D005998:Glycine / Q000378:metabolism*; D050487:Glycine Plasma Membrane Transport Proteins; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D012521:Sarcosine / Q000031:analogs & derivatives / Q000494:pharmacology
D026921:Amino Acid Transport Systems, Neutral; D050487:Glycine Plasma Membrane Transport Proteins; C479537:Org 24461; C493266:Slc6a9 protein, rat; D005998:Glycine; D012521:Sarcosine